Cargando…
Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials
Antipsychotic-induced dyslipidemia could increase the risk of cardiovascular diseases. This is a meta-analysis of randomized double-blind placebo-controlled trials to examine the efficacy and safety of adjunctive metformin for dyslipidemia induced by antipsychotics in schizophrenia. The standardized...
Autores principales: | Jiang, Wen-Long, Cai, Dong-Bin, Yin, Fei, Zhang, Ling, Zhao, Xi-Wu, He, Jie, Ng, Chee H., Ungvari, Gabor S., Sim, Kang, Hu, Mei-Ling, Zheng, Wei, Xiang, Yu-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181777/ https://www.ncbi.nlm.nih.gov/pubmed/32327628 http://dx.doi.org/10.1038/s41398-020-0785-y |
Ejemplares similares
-
Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia
por: UNGVARI, Gabor S., et al.
Publicado: (2018) -
Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae–Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ling, et al.
Publicado: (2021) -
Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019) -
Effect of adjunctive ranitidine for antipsychotic-induced weight
gain: A systematic review of randomized placebo-controlled
trials
por: Gu, Xiao-Jing, et al.
Publicado: (2017) -
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials
por: Wu, R-R, et al.
Publicado: (2016)